Laddar...

Rescue of tolerant CD8(+) T cells during cancer immunotherapy with IL2:antibody complexes

Interleukin-2 (IL2) was among the earliest reagents used for cancer immunotherapy due to its ability to support the survival and function of tumor-reactive T cells. However, treatment with IL2 is accompanied by off-target toxicity and low response rates in patients. In mouse models, these issues are...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Immunol Res
Huvudupphovsmän: Klevorn, Lauryn E., Berrien-Elliott, Melissa M., Yuan, Jinyun, Kuehm, Lindsey M., Felock, Gregory D., Crowe, Sean A., Teague, Ryan M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5135645/
https://ncbi.nlm.nih.gov/pubmed/27803062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0159
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!